NCT07206056
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07206056
Title An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01) (TulmiSTAR-01)
Acronym TulmiSTAR-01
Recruitment Recruiting
Gender male
Phase Phase Ib/II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | POL | ESP | DNK | AUS

Facility Status City State Zip Country Details
Sarah Cannon Research Institute RECRUITING Denver Colorado 80218 United States Details
Sarah Cannon Research Institute RECRUITING Jacksonville Florida 32256 United States Details
Wichita Urology Group PA RECRUITING Wichita Kansas 67226 United States Details
Fred Hutchinson Cancer Research Center RECRUITING Seattle Washington 98109-1024 United States Details
Novartis Investigative Site RECRUITING St Leonards New South Wales 2065 Australia Details
Novartis Investigative Site RECRUITING Liverpool 2170 Australia Details
Novartis Investigative Site RECRUITING Vejle DK-7100 Denmark Details
Novartis Investigative Site RECRUITING Kuching Sarawak 93586 Malaysia Details
Novartis Investigative Site RECRUITING Poznan 60-192 Poland Details
Novartis Investigative Site RECRUITING Singapore 119074 Singapore Details
Novartis Investigative Site RECRUITING Singapore S308433 Singapore Details
Novartis Investigative Site RECRUITING Madrid 28041 Spain Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field